{
  "id": 10962211,
  "title": "#EASD26: Lilly's amylin-Zepbound combo posts best-ever weight loss in patients with obesity and diabetes",
  "url": "https://urgent.news/2026/09/30/easd26-lillys-amylin-zepbound-combo-posts-best-ever-weight-loss-in",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-30T14:15:13.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/easd26-lillys-amylin-zepbound-combo-posts-best-ever-weight-loss-in-patients-with-obesity-and-diabetes/"
  },
  "original_language": "en",
  "account": null,
  "summary": "MILAN — Forget Wegovy and Zepbound. Never mind CagriSema, and even retatrutide. The latest big name in obesity is eloraTZP. Data revealed Wednesday show that Lilly's amylin-incretin combination delivered weight loss of up to 23.3% at ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}